Prophylactic HIV Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.10 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Prophylactic HIV Drugs Market Analysis
The prophylactic human immunodeficiency virus (HIV) drug market is expected to register a CAGR of 4.1% during the forecast period.
- The novel COVID-19 augmented the need to evaluate the antiretroviral drugs to treat COVID-19 infections. The drugs such as lopinavir and ritonavir, used in combination to treat HIV, were repurposed to treat COVID-19 infections. Several countries have evaluated the potential of these antiretroviral drugs for treating coronavirus infection. For instance, in November 2021, Pfizer reported the submission of an application to the United States Food and Drug Administration (US FDA) for emergency use authorization for its investigational oral drug combination for COVID-19, ritonavir-boosted PF-07321332.
- Additionally, according to the study published in the National Library of Medicine in January 2022, between March and April 2020, hospital utilization of ritonavir-boosted lopinavir increased eightfold. As a result, the studied market was significantly impacted by the COVID-19 pandemic. However, the market is growing at a stable pace due to a resumption of diagnosis procedures, manufacturing activities, and the availability of products. It is expected to witness a similar trend over the coming years.
- The major factors driving the market's growth are the high prevalence of HIV globally. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) factsheet 2022, in 2021, 38.4 million individuals were living with HIV, and 1.5 million were newly infected with the virus. In 2021, 28.7 million people will have access to antiretroviral medication. As a result of the high prevalence of HIV globally, demand for prophylactic HIV medications is predicted to rise, propelling market growth throughout the forecast period.
- A large number of non-profit organizations and pharmaceutical and biotechnology companies are investing in HIV clinical research for the development of advanced drugs, which is likely to propel the growth of the market. For instance, in August 2022, US Department of Health and Human Services (HHS) Secretary Xavier Becerra announced more than USD 20 million in funding to enhance HIV prevention, testing, and treatment services at health centers in the US at the National Ryan White Conference on HIV Care and Treatment. The health centers that receive this grant will use it to increase access to HIV prevention drugs (including pre-exposure prophylaxis, PrEP, and related services).
- In addition, product launches and approval by the regulatory authority are expected to support market expansion over the forecast period. For instance, in October 2022, Excision reported that the FDA had approved it as Investigational New Drug (IND) as a treatment to prevent HIV, called EBT-101. Thus, such efforts by market participants may result in the launch of advanced preventive therapy, which is expected to boost market growth over the forecast period. However, lower penetration in an underdeveloped market and side effects associated with this drug, such as vomiting, nausea, tiredness, and diarrhea, may restrain the market's growth.
Prophylactic HIV Drugs Market Trends
Oral Drug Forms Segment is Expected to Hold a Significant Share Over the Forecast Period
- The oral drug segment is expected to dominate the global prophylactic HIV drug market over the forecast period. This can be attributed to new product development and the presence of a strong pipeline coupled with rising product approvals. The oral route also has several pharmacokinetic advantages, such as a higher rate of bioavailability, rapid drug delivery, and high efficacy. All these advantages are expected to propel segment growth.
- The oral route is the most patient-compliant; therefore, it is most widely adopted by patients. Also, the development of promising new drugs and potential clinical pipeline candidates are some of the major factors expected to drive segment growth.
- For instance, in March 2022, ViiV Healthcare, a company majority owned by GlaxoSmithKline plc with Pfizer Inc. and Shionogi Limited as shareholders, reported that the US Food and Drug Administration (FDA) approved a label update for Cabenuva (cabotegravir and rilpivirine). Additionally, in June 2022, Cipla Ltd. and its partner Drugs for Neglected Diseases Initiative (DNDi) reported the availability of a 4-in-1 antiretroviral medication for HIV-positive youngsters in South Africa. The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable, and "4-in-1" fixed-dose combination of four antiretroviral (ARV) medications created specifically for newborns and young children with HIV.
- The future growth of the market is anticipated to be fueled by the launch of various potential pipeline candidates, such as fostemsavir and PRO 140, and the launch of generic versions of various branded drugs, such as tenofovir disoproxil fumarate tablets. Thus, all the aforementioned factors, such as the launch of an oral drug, are expected to boost segment growth over the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
- North America is one of the strongest regions and is also an important revenue contributor to the global HIV prophylactic drug market. Heightened awareness of disease-remitting therapies among patients, the presence of a technologically advanced healthcare framework, and supportive reimbursement policies are stimulating the growth of the region.
- As per the Department of Health and Human Services, in 2020, 30.6 thousand people will receive an HIV diagnosis in the United States and its dependent areas. Similarly, according to the HIV Surveillance Report 2021, over 2,132 HIV diagnoses were reported in Canada, 5.6 per 100,000 population. The age group 30 to 39 years had the highest HIV diagnosis rate at 12.7 per 100,000 population. Thus, the growing prevalence of HIV in the region is expected to propel the growth of the market over the forecast period.
- In addition, increasing government funding and programs for HIV prevention and treatment are expected to boost the market over the forecast period. For instance, for the fiscal year 2023, the US government's spending on the domestic fight against HIV has increased to more than USD 28 billion annually. This sum includes both discretionary and required spending for Medicare, Medicaid, Social Security payouts, and other required spending. Hence, owing to all the aforementioned factors, the North American region is anticipated to grow at high rates.
Prophylactic HIV Drugs Industry Overview
The prophylactic HIV drug market is fragmented, with the presence of several players. Some of the prominent market participants are AbbVie, APOTEX INC., Auro Pharma Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche AG (Genentech Inc.), Johnson & Johnson Health Care Systems Inc., Gilead Sciences Inc., Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd. and GlaxoSmithKline plc (ViiV Healthcare Group of Companies).
Prophylactic HIV Drugs Market Leaders
Merck & Co., Inc.
Cipla Inc
Bristol-Myers Squibb Company
Viatris Inc. (Mylan)
Johnson & Johnson
*Disclaimer: Major Players sorted in no particular order
Prophylactic HIV Drugs Market News
- December 2022: The United State Food and Drug Administration (US FDA) approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations.
- In February 2022: The United State Food and Drug Administration (US FDA) approved rilpivirine and cabotegravir (Cabenuva) for 2-month dosing for adults living with HIV-1 infection.
Prophylactic HIV Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of HIV/AIDS
4.2.2 Increasing Government Initiatives
4.2.3 Increasing R&D Activities
4.3 Market Restraints
4.3.1 Lower Penetration in Underdeveloped Markets
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Drug
5.1.1 Tenofovir
5.1.2 Emtricitabine
5.1.3 Other Drugs
5.2 By Dosage Form
5.2.1 Oral
5.2.2 Topical
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie
6.1.2 SK Capital (APOTEX INC.)
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 Bristol-Myers Squibb Company
6.1.5 Cipla Inc.
6.1.6 GalaxoSmithKline PLC
6.1.7 F. Hoffmann-La Roche AG (Genentech Inc.)
6.1.8 Gilead Sciences Inc.
6.1.9 Johnson & Johnson
6.1.10 Merck & Co. Inc.
6.1.11 Viatris Inc. (Mylan)
6.1.12 Pfizer Inc.
6.1.13 Teva Pharmaceutical Industries Ltd
6.1.14 GlaxoSmithKline plc (ViiV Healthcare Group of Companies)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Prophylactic HIV Drugs Industry Segmentation
As per the scope of the report, human immunodeficiency virus (HIV) is a chronic and life-threatening disease. The disease can be transferred from one person to another through blood-to-blood or sexual contact. HIV prophylactics drugs are the medication that is given to prevent HIV disease before it even occurs.
The prophylactic HIV drugs market is segmented by drug (tenofovir, emtricitabine, and other drugs), dosage form (oral and topical), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally.
The report offers the value (in USD million) for the above segments.
| By Drug | |
| Tenofovir | |
| Emtricitabine | |
| Other Drugs |
| By Dosage Form | |
| Oral | |
| Topical |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Prophylactic HIV Drugs Market Research FAQs
What is the current Prophylactic HIV Drugs Market size?
The Prophylactic HIV Drugs Market is projected to register a CAGR of 4.10% during the forecast period (2024-2029)
Who are the key players in Prophylactic HIV Drugs Market?
Merck & Co., Inc. , Cipla Inc , Bristol-Myers Squibb Company, Viatris Inc. (Mylan) and Johnson & Johnson are the major companies operating in the Prophylactic HIV Drugs Market.
Which is the fastest growing region in Prophylactic HIV Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Prophylactic HIV Drugs Market?
In 2024, the North America accounts for the largest market share in Prophylactic HIV Drugs Market.
What years does this Prophylactic HIV Drugs Market cover?
The report covers the Prophylactic HIV Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Prophylactic HIV Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Prophylactic HIV Drugs Industry Report
Statistics for the 2024 Prophylactic HIV Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Prophylactic HIV Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
